Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bristow

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomasChih-Yi Hsu, Robert Bristow, Moon Seok Cha, et al.
Radiation Oncology (London, England)|November 6, 2009
Image guided dose escalated prostate radiotherapy: still room to improveJarad M Martin, Andrew Bayley, Robert Bristow, et al.
Cancers|December 11, 2022
T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC)Luca G Campana, Wasat Mansoor, James Hill, et al.
Cancer Research|July 10, 2007
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation responseMichael Milosevic, Peter Chung, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|April 12, 2011
Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapyDanny Vesprini, Michael Sia, Gina Lockwood, et al.
The Journal of Experimental Medicine|April 14, 2010
Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancerLi Li, Marie-Jo Halaby, Anne Hakem, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2014
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumorsMonica Mita, Michael Gordon, Lee Rosen, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 2007
Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinomaJarad M Martin, Tara Rosewall, Andrew Bayley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysisJi Hyun Kim, Myong Cheol Lim, Eun Taeg Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2012
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancerMichael Milosevic, Padraig Warde, Cynthia Ménard, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomasChih-Yi Hsu, Robert Bristow, Moon Seok Cha, et al.
Radiation Oncology (London, England)|November 6, 2009
Image guided dose escalated prostate radiotherapy: still room to improveJarad M Martin, Andrew Bayley, Robert Bristow, et al.
Cancers|December 11, 2022
T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC)Luca G Campana, Wasat Mansoor, James Hill, et al.
Cancer Research|July 10, 2007
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation responseMichael Milosevic, Peter Chung, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|April 12, 2011
Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapyDanny Vesprini, Michael Sia, Gina Lockwood, et al.
The Journal of Experimental Medicine|April 14, 2010
Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancerLi Li, Marie-Jo Halaby, Anne Hakem, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2014
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumorsMonica Mita, Michael Gordon, Lee Rosen, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 2007
Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinomaJarad M Martin, Tara Rosewall, Andrew Bayley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysisJi Hyun Kim, Myong Cheol Lim, Eun Taeg Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2012
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancerMichael Milosevic, Padraig Warde, Cynthia Ménard, et al.
Pageof 6